The tetravalent tribe of the dengue vaccine (TV003/TV005) originally developed by national healthcare institutions, the US, has shown promising results in foreclinical and clinical trials around the world. Picture of a representative file Photo Credit: Hind
After the announcement of the Indian Council for Medical Research (ICMR) and Panacea Biotec limited to starting the third phase tests, approximately 8,000 targeted 10,000 participants were entered in the third phase of clinical evaluation for vaccine against Dengue in India, Manoj Murhekar, National Institute of Epidemiology, ICMR, Chennai, Chennai.
The court will be introduced in 20 centers across the country, said Dr. Murhekar. “In India, it is known that all four dengue serotypes circulate or together in many regions, so it is necessary to ensure that we have an effective vaccine that achieves good efficiency for all four serotypes,” he added.
The exam is primarily financed by ICMR, with partial support from Panacea Biotec. Participants will be monitored for two years under projects extended across different centers, including Chennai, Pune, Hyderabad and Delhi.
There is currently no antiviral treatment or licensed vaccine for Dengue in India.
“This milestone will evaluate the effectiveness of the Indian original tetravalent vaccine against Dengue, Denegiel, developed by Panacea Biotec. The first participant of this court was vaccinated last year in Pandit Bhagwat Dayal Sharma after the postgraduate institution of medical sciences, Rohtak, ‘the release of the Union.
The tetravalent tribe of the dengue vaccine (TV003/TV005) originally developed by national healthcare institutions, the US, has shown promising results in foreclinical and clinical trials around the world. Panacea Biotec, one of the three Indian companies that receives the tribe, is at the most advanced stage of the development of the vaccine. The company worked considerably on these strains to develop a full formulation of the vaccine and hold the process of the process for this work. The first and second phase of clinical studies of Indian formulations of the vaccine was completed in 2018-19, which brought promising results.
Dengue is the main problem in public health in India, which is one of the 30 best countries with the highest occurrence of the disease. The global incidence of dengue has been increasing in the last two decades, according to the World Health Organization (WHO), more than 129 countries have been showing by the end of 2023.
In India, approximately 75-80% of asymptomatic infections are, but these individuals can still transmit the infection by biting the mosquitoes of Aedes. Between 20-25% of cases where the symptoms are obvious, children are exposed to significantly higher risk of hospitalization and mortality. In adults, the disease can escalate to serious conditions, including the dengue haemorrhagic fever and dengue shock syndrome. The dengue virus has four serotypes, 1-4, with low cross protection against each other, which means that individuals can experience repeated infections.
Published – July 12, 2025 20:13
